H.C. Wainwright raised the firm’s price target on Arcus Biosciences (RCUS) to $28 from $24 and keeps a Buy rating on the shares following the Q3 report. The firm says the LITESPARK-022 trial shows potential for HIF2 alpha inhibitors to be used in early treatment of renal cell carcinoma.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Reports Promising Q3 2025 Results
- Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)
- Arcus Biosciences Advances Cancer Treatment with AB801 Study
- Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma
- Arcus Biosciences’ Promising Phase 1 Study on Renal Cell Carcinoma